Skip to main content
NCBI home page
Stem Cells and Development logoLink to Stem Cells and Development
. 2012 Feb 8;21(13):2541–2551. doi: 10.1089/scd.2011.0711

EGFR Ligands Drive Multipotential Stromal Cells to Produce Multiple Growth Factors and Cytokines via Early Growth Response-1

Svetoslava S Kerpedjieva 1,*,†, Duk Soo Kim 1,*, Dominique J Barbeau 1, Kenichi Tamama 1,2,✉
PMCID: PMC3424970  PMID: 22316125

Abstract

Cell therapy with adult bone marrow multipotential stromal cells/mesenchymal stem cells (MSCs) presents a promising approach to promote wound healing and tissue regeneration. The strong paracrine capability of various growth factors and cytokines is a key mechanism of MSC-mediated wound healing and tissue regeneration, and the goal of this study is to understand the underlying mechanism that supports the strong paracrine machineries in MSCs. Microarray database analyses revealed that early growth response-1 (EGR1) is highly expressed in MSCs. Our previous studies showed that epidermal growth factor (EGF) treatment induces growth factor production in MSCs in vitro. Since EGF strongly upregulates EGR1, we hypothesized that EGF receptor (EGFR)–EGR1 signaling plays a pivotal role in MSC paracrine activity. EGF treatment upregulated the gene expression of growth factors and cytokines, including EGFR ligands in a protein kinase C (PKC)- and/or mitogen-activated protein kinase–extracellular-signal-regulated kinase-dependent manner, and it was reversed by shRNA against EGR1. PKC activator phorbol 12-myristate 13-acetate enhanced EGFR tyrosyl phosphorylation and upregulated the gene expression of growth factors and cytokines in a heparin-binding EGF-like growth factor (HBEGF) inhibitor CRM197 sensitive manner, indicating an involvement of autocrined HBEGF in the downstream of PKC signaling. Moreover, stimulation with growth factors and cytokines induced the expression of EGFR ligands, presumably via EGR1 upregulation. These data indicate EGR1 as a convergence point of multiple signaling pathways, which in turn augments the production of multiple growth factors and cytokines by enhancing the autocrine signaling with EGFR ligands.

Introduction

Cell therapy with adult multipotential stromal cells or mesenchymal stem cells (MSCs) is a promising approach against various diseases, such as chronic nonhealing wounds or coronary arterial disease, as these cells promote angiogenesis and tissue regeneration upon cell transplantation [1–11]. These cells were originally isolated as colony-forming adherent fibroblast-like cells or colony-forming unit fibroblastic cells from bone marrow suspension [12], but it was subsequently realized that these cells carry multipotency, that is, capable of differentiating into multiple cell lineages, including osteoblasts, chondrocytes, adipocytes, and other types of cells [7–10,13,14].

Initially, MSC differentiation and direct incorporation into local tissues undergoing wound healing and tissue regeneration was regarded as the primary mechanism of MSC action; however, the strong paracrine capability of various growth factors and cytokines secreted by MSCs is now recognized as a key underlying mechanism of MSC-mediated wound healing and tissue regeneration [15]. The conditioned medium of MSCs, which contains these growth factors and cytokines, was shown to exert tissue regenerative effects as well as further support for the importance of this mechanism [16–19]. This study was aimed to understand the molecular mechanism that supports the strong paracrine machineries in MSCs.

Early growth response-1 (EGR1) encodes a zinc finger transcription factor that exemplifies a group of immediate-early response genes, since a variety of stimulations, including growth factors, cytokines, and even noxious stimuli, rapidly and transiently induce its expression. The induced EGR1 in turn binds to the EGR response element in the promoter regions of growth factors and cytokines and upregulates these genes. Thus, EGR1 may function as a converging point for many signaling pathways [20,21].

Microarray database analyses revealed that EGR1 is highly expressed in MSCs. We and others showed that the treatment with epidermal growth factor (EGF) or transforming growth factor alpha (TGFα), another EGF receptor (EGFR) ligand, induces growth factor production in MSCs in vitro [22–24]. Moreover, the pretreatment with TGFα was shown to confer additional organ-protective effects on the transplanted MSCs by enhancing paracrine activity of MSCs [25,26]. Since EGF is a strong inducer of EGR1 in MSCs (Fig. 2), we hypothesized that EGFR–EGR1 signaling plays a pivotal role in MSC paracrine activity.

FIG. 2.

FIG. 2.

Open in a new tab

(A) Effects of MSC treatments with various growth factors and cytokines on the induction of EGR1. MSCs were stimulated with epidermal growth factor (EGF) (10 nM), PDGF-AA (30 ng/mL), PDGF-BB (30 ng/mL), vascular endothelial growth factor A (VEGFA) (100 ng/mL), hepatocyte growth factor (HGF) (50 ng/mL), FGF2 (30 ng/mL), leukemia inhibitory factor (LIF) (10 ng/mL), interleukin 6 (IL6) (10 ng/mL), and IL11 (10 ng/mL) for 1 h and the total RNA was harvested for gene expression analysis (*P<0.05, **P<0.005 to vehicle control in each analyte). (B–E) Effects of EGF stimulation on the gene expression in MSCs. MSCs were treated with 10 nM EGF for 4 h (B); 1, 4, and 16 h (C); or 24 h (D and E) and gene expression was evaluated in mRNA (B and C) or in protein (D and E). (B) Human growth factor PCR array data. The relative expression levels for each gene in the control and EGF-stimulated samples are plotted against each other in the scatter plot. The genes upregulated or downregulated by at least 2-fold in the EGF-treated MSCs relative to nontreated MSCs are indicated in the figure. The upregulated genes are shown with filled dots, whereas the downregulated genes are shown with faint dots. (C) The gene expression of various growth factors and cytokines evaluated by qRT-PCR with Taqman primers (*P<0.05, **P<0.005 to 0 h control in each analyte). (D and E) Production of heparin-binding EGF-like growth factor (HBEGF) (D) and IL6 (E) in the conditioned media by ELISA (*P<0.05, **P<0.005 to vehicle control in each analyte). (F) The scatter plot of growth factor profiles between EGF-stimulated MSCs and HBEGF-stimulated MSCs by human growth factor PCR array.

Materials and Methods

Materials

Dulbecco's modified Eagle medium (DMEM) culture medium, cell culture supplements, and all of the reagents for polymerase chain reaction (PCR) were from Life Technologies. Fetal bovine serum (FBS) and Lentivirus Mission® shRNA vectors were from Sigma. All growth factors and cytokines were from Life Technologies or Peprotech. P42/44 mitogen-activated protein kinase–extracellular-signal-regulated kinase (MAPK-ERK) kinase (MEK) inhibitor PD98059 was from EMD Biosciences. Pan protein kinase C (PKC) inhibitor bisindolylmaleimide I (BIM) was from Cayman Chemical. All other reagents were from Sigma or Life Technologies, unless described otherwise.

This study was approved by the IBC committee of the University of Pittsburgh for recombinant DNA research and biohazard agents in obedience to National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules.

Cell culture

Human telomerase reverse transcriptase—immortalized human bone marrow MSCs were the kind gift of Dr. Junya Toguchida (Kyoto University, Kyoto, Japan) [27], and were cultured in DMEM supplemented with 10% FBS (Atlanta Biological), 2 mM L-glutamine, 1 mM pyruvate, and 100 mM nonessential amino acid. We confirmed the multipotency of the immortalized MSCs into osteogenic, adipogenic, and chondrogenic lineages previously [7,14].

Quantitative reverse transcription-PCR and PCR array

The level of mRNA transcripts was assessed by 2-step quantitative reverse transcription–polymerase chain reaction (qRT-PCR) for both Taqman® PCR (Life Technologies) and Sybr-green-based PCR array (Qiagen). Mx3005P (Stratagene) was used as a quantitative real-time PCR thermal cycler.

For Taqman PCR, total RNA was prepared with TRIzol plus according to the manufacturer's instruction. In brief, after DNase treatment for the removal of possible contaminated genomic DNA, cDNA was synthesized from total RNA with High Capacity RNA-to-DNA kit (Life Technologies) for Taqman PCR. Then, cDNA was mixed with Brilliant III Ultra Fast QPCR Master Mix (Agilent Technologies) and each Taqman gene-specific probe/primers and subjected to the following PCR: 95°C for 3 min, and then 40 cycles of 2-temperature PCR at 95°C for 15 s for denaturing and 60°C for 30 s for annealing and extension.

The Taqman probe/primers (Life Technologies) used in this study are listed in Table 1. Taqman probe/primers for human ribosomal protein, large, P0 (RPLP0) (4333761F) were used as an endogenous invariant control (housekeeping gene) (Life Technologies). All PCR primers were designed to span intron(s) to discriminate cDNA amplicons from genomic amplicons according to the manufacturer. Amplification efficacy of each PCR was assessed initially with serial dilution of control samples; those fell into 95%–105%. Comparative Ct method was utilized to assess the levels of each mRNA transcript relative to that level of RPLP0 mRNA transcript.

Table 1.

Taqman Primers Used in This Study

EGR1 Early growth response-1 Hs00152928_m1
EGF Epidermal growth factor Hs01099999_m1
HBEGF Heparin-binding EGF-like growth factor Hs00961131_m1
AREG Amphiregulin Hs00950669_m1
VEGFA Vascular endothelial growth factor A Hs00900055_m1
PDGFA Platelet-derived growth factor alpha Hs00234994_m1
PDGFB Platelet-derived growth factor beta Hs00966522_m1
HGF Hepatocyte growth factor Hs00300159_m1
FGF2 Fibroblast growth factor 2 (basic) Hs00266645_m1
LIF Leukemia inhibitory factor Hs00171455_m1
IL6 Interleukin 6 Hs00985639_m1
IL11 Interleukin 11 Hs00174148_m1
EGFR Epidermal growth factor receptor Hs01076078_m1
ERRB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 Hs01001580_m1
PDGFRA Platelet-derived growth factor receptor, alpha Hs00998018_m1
PDGFRB Platelet-derived growth factor receptor, beta Hs01019589_m1
MET Met proto-oncogene (hepatocyte growth factor receptor) Hs01565584_m1
KDR Kinase insert domain receptor Hs00911700_m1
FLT1 Fms-related tyrosine kinase 1 Hs01052961_m1
LIFR Leukemia inhibitory factor receptor alpha Hs01123581_m1
IL6R Interleukin 6 receptor Hs01075667_m1
IL11RA Interleukin 11 receptor, alpha Hs00234415_m1
Open in a new tab

The Human Growth Factors RT2 Profiler™ PCR Array (PAHS-041) (Qiagen) was also utilized to profile the expression of 84 genes related to growth factors (Supplementary Table S1; Supplementary information is available online at www.liebertonline.com/scd), according to the manufacturer's instruction. In brief, after DNase treatment on the total RNA, cDNA was synthesized from total RNA with RT2 First Strand Kit (Qiagen). Then, cDNA was mixed with SABiosciences RT2 qPCR Master Mix (Qiagen), loaded to the PCR array well preloaded with specific probes, and subjected to the following thermocycle: 95°C for 10 min, and then 40 cycles of 2-temperature PCR at 95°C for 15 s for denaturing and 60°C for 1 min for annealing and extension. At the completion of the thermocycling program, melting curve analysis was conducted to ensure the specificity of the amplicons. The resulting Ct values for all wells were uploaded at [http://sabiosciences.com/pcrarraydataanalysis.php] for Web-based PCR array data software that analyzes the gene expression with delta-delta Ct method with endogenous controls listed in Supplementary Table S1. The relative expression levels for each gene in the 2 samples are plotted against each other in the scatter plot.

Gene knockdown with shRNA

The anti-EGR1 shRNA (TRCN0000273850: CCGGCATCTCTCTGAACAACGAGAACTCGAGTTCTCGTTGTTCAGAGAGATGTTTTTG) and nontarget shRNA control vector (CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT) were purchased from Sigma-Aldrich. Immortalized MSCs plated on 24-well plate at 4.4×103 cells were infected with shRNA lentivirus at MOI of 100 in the presence of 8 μg/mL polybrene.

Puromycin-containing selection medium was used after day 3 to isolate the cells stably expressing transfected shRNAs. Lentivirus-mediated nonspecific interferon response was evaluated by IFNr qRT-Primers (Invivogen) and was shown to be minimal (data not shown).

Cell signaling immunoassay

Luminex® xMAP® technology-based MILLIPLEX MAP Cell Signaling MAPmates™ multiplex assay kit (Millipore) was used for intracellular signaling immunoassays. Briefly, cells were lysed on ice in a MILLIPLEX MAP Lysis Buffer containing proteinase and phosphatase inhibitors (Millipore). After removing particulate matter by filtration, lysates were mixed with MILLIPLEX MAP Assay Buffer (Millipore) containing MILLIPLEX MAP capture beads (Millipore) for the target analytes and incubated overnight at 4°C. After removing the supernatant and washing, the beads were incubated with MILLIPLEX MAP Detection Antibodies (Millipore) for 1 h at room temperature in a light-protected condition. After removing supernatant and washing, the beads were re-suspended in MILLIPLEX MAP Assay Buffer (Millipore) and analyzed by Luminex 200™ (Luminex Corp.). Nonstimulated HeLa cell lysate (Millipore) was used as a negative cell lysate control, whereas EGF-stimulated A431 cell lysate (Millipore) was used as a positive cell lysate control.

Quantitation of secreted heparin-binding EGF-like growth factor and IL6

After rinsing with PBS, MSCs were cultured in 0.1% FBS-containing serum-free medium for 24 h during treatment with 10 nM EGF. The conditioned media were collected and the secreted heparin-binding EGF-like growth factor (HBEGF) and interleukin 6 (IL6) were measured by quantitative ELISA kits according to each manufactures' instructions (Siloam Biosciences, Inc.) (RayBiotech, Inc.). The readouts were adjusted per 1×106 cells.

Microarray database analysis

DNA microarray dataset already deposited to the Gene Expression Omnibus (GEO) by Kubo et al. [28] (GSE9451) was used in this study. This dataset was generated from total RNA isolated from human iliac MSCs and human skin and gingival fibroblasts, which were obtained from commercial sources (BioWhittaker, Inc., now Lonza and KURABO) or from patients at Hiroshima University Hospital (Hiroshima, Japan) under the protocol approved by ethical authorities at Hiroshima University [28,29]. The DNA microarray dataset was further analyzed with the online ingenuity pathway analysis software [www.ingenuity.com] and each identifier was mapped to its corresponding gene through core analysis. The average gene expression was calculated through comparison analysis for fibroblasts as well as MSCs in biological triplicate.

According to the GEO database, the microarray dataset was produced by using KURABO GeneChip Custom Analysis Service with Human Genome U133 Plus 2.0 chips (Affymetrix, Inc.) for fibroblasts and MSCs in biological triplicate and deposited to the GEO after normalization by using GeneSpring (Silicon Genetics) [28].

Statistical analysis

All experiments were performed in duplicate or triplicate. Data were analyzed using Student's t-tests. Significance was set at P<0.05 or more stringent as noted in the text and figure legends.

Results

MSCs express EGR1 higher than fibroblasts in microarray database

By using GEO repository, we found that EGR1 expresses higher in MSCs than in fibroblasts in baseline condition in GSE9451 (Fibroblast, 325.5; MSC, 1223.8; P=0.002) [28]. This strong expression of EGR1 also indicates that cultured MSCs are in an activated state, as suggested by Caplan [15].

The encyclopedia of DNA elements (ENCODE) project consortium was launched with the aim to build a comprehensive parts list of functional elements in the human genome [30,31]. In the ENCODE database, EGR1 was shown to bind to the putative promoter regions of various growth factors and cytokines and their cognate receptors, including HBEGF; platelet-derived growth factor alpha (PDGFA); platelet-derived growth factor beta (PDGFB); vascular endothelial growth factor A (VEGFA); IL6; IL11; PDGF receptor, alpha (PDGFRA); PDGF receptor, beta (PDGFRB); met proto-oncogene (MET); IL6 receptor (IL6R); and IL11 receptor alpha (IL11RA) (data not shown).

PKC activator phorbol 12-myristate 13-acetate strongly induces EGR1 and multiple growth factor/cytokine production

One of the upstream signaling pathways strongly inducing EGR1 expression is the PKC pathway [32], which is activated by various growth factors and cytokines [33]. PKC pathway activator phorbol 12-myristate 13-acetate (PMA) upregulated the gene expression of various growth factors/cytokines, including HBEGF and amphiregulin (AREG), which are EGFR ligands (Fig. 1A, C), in addition to EGR1 (Fig. 1B). Besides growth factors and cytokines, PMA treatment also upregulated cognate receptors of these growth factors and cytokines (Fig. 1D, E), indicating the possible presence of autocrine loop(s), possibly via EGR1.

FIG. 1.

FIG. 1.

Open in a new tab

Effects of phorbol 12-myristate 13-acetate (PMA) stimulation on the gene expression in mesenchymal stem cells (MSCs). MSCs were treated with 100 ng/mL PMA for 1 h (B) or 4 h (A, C, D, and E) and total RNA was collected for evaluation of the gene expression. (A) Human growth factor polymerase chain reaction (PCR) array data. The relative expression levels for each gene in the control and PMA-stimulated samples are plotted against each other in the scatter plot. The genes upregulated or downregulated by at least 2-fold in the PMA-treated MSCs relative to nontreated MSCs are indicated in the figure. The upregulated genes are shown with filled dots, whereas the downregulated genes are shown with faint dots. (B–E) The gene expression of early growth response-1 (EGR1) (B), growth factors and cytokines (C), and cognate receptors (D and E) evaluated by quantitative reverse transcription–polymerase chain reaction (qRT-PCR) with Taqman® primers (*P<0.05, **P<0.005 to vehicle control in each analyte).

EGFR ligand strongly induces EGR1 and upregulates the production of growth factors and cytokines including EGFR ligands

Among the growth factors and cytokines studied in Fig. 1, EGF, PDGF-AA, PDGF-BB, hepatocyte growth factor (HGF), and fibroblast growth factor-2 (FGF2) strongly induced EGR1 expression (Fig. 2A). These data strongly suggest that the PKC-EGR1 pathway is a common signaling pathway activated by multiple growth factors, and the pathway activation in turn upregulates the gene expression of various growth factors and cytokines. Among these growth factors and cytokines, we singled out EGFR ligands, because EGFR ligands are the only ligands that are strongly upregulated along with their cognate receptor EGFR by PMA treatment (Fig. 1) and in turn strongly induced EGR1 in MSCs (Fig. 2A). We initially chose EGF as a representative EGFR ligand, because it is the most-studied one [7,34]. EGF treatment also upregulated multiple growth factors and cytokines in mRNA transcripts (Fig. 2B, C). The EGF-initiated upregulation of growth factors and cytokines was further confirmed in protein levels for HBEGF (5.67±0.24 pg/106 cells under EGF stimulation; 2.03±0.10 pg/106 cells in vehicle control, P<0.005) and IL6 (1.07±0.06 ng/106 cells under EGF stimulation; 0.71±0.02 ng/106 cells in vehicle control, P<0.05) (Fig. 2D, E), as HBEGF is a representative EGFR ligand as well as the key molecule of the EGFR signaling in MSCs in this study, whereas previous publications suggested the critical roles of IL6 in MSC biology [35,36]. We have already published the protein concentrations of VEGF, HGF, and FGF2 in EGF-stimulated MSC supernatants [23]. Interestingly, EGF treatment upregulated other EGFR ligands, HBEGF and AREG (Fig. 2B–D).

Though HBEGF is known to bind to v-erb-b2 erythroblastic leukemia viral oncogene homolog 4 (ErbB4) in addition to EGFR [37], MSCs express ErbB4 in only trace amounts in the microarray database GSE9451 [28] and ErbB4 protein expression was not observed in human MSCs [38]. Thus, EGFR should be the only functional receptor expressed on MSCs. Indeed, the intracellular signaling elicited by HBEGF stimulation should be similar to that by EGF stimulation, as we showed previously [7]. The gene expression profiles of growth factors and cytokines were also very similar between EGF-stimulated MSCs and HBEGF-stimulated MSCs (Fig. 2F).

Those data are indicative of possible existence of autocrine loops with EGFR ligands via EGR1 in MSCs.

EGF treatment upregulates the gene expression of EGR1, growth factors, and cytokines in a PKC- and/or MAPK-ERK-dependent manner

Next, we investigated the signaling pathways in the downstream of EGFR by using pharmacological inhibitors. Pan PKC inhibitor BIM, as well as MEK inhibitor PD98059, reduced the EGR1 induction by EGF (Fig. 3A). Similarly, the induction of PDGFA, VEGFA, IL6, and IL11 was reduced by BIM as well as by PD98059 (Fig. 3D, F, H, I). The HBEGF induction was reversed by BIM, but not by PD98059 (Fig. 3B), whereas the AREG induction was reversed by PD98059, but not by BIM (Fig. 3C). EGF stimulation activated MAPK-ERK and c-Jun N-terminal kinase (JNK) pathways in the downstream of EGFR tyrosyl phosphorylation in MSCs (Fig. 3J–L). Interestingly, BIM treatment appeared to increase the PDGFB and leukemia inhibitory factor (LIF) expression (Fig. 3E, G), even though the expression of those genes was induced by PKC activator PMA (Fig. 1C). The underlying mechanism remains unclear, but disinhibition of PKC-mediated EGFR signal inhibition by BIM [39,40] might induce the enhancement of EGFR downstream signaling (Fig. 3J–L) and cause this paradoxical increase of PDGFB and LIF expression (Fig. 3E, G).

FIG. 3.

FIG. 3.

Open in a new tab

Effects of pan protein kinase C (PKC) inhibitor bisindolylmaleimide I (BIM) and mitogen-activated protein kinase–extracellular-signal-regulated kinase (MAPK-ERK) kinase (MEK) inhibitor PD98059 on the gene expression of EGR1 (A) and various growth factors and cytokines (B–I) by qRT-PCR with Taqman primers and the phosphorylation of EGFR (J), MAPK-ERK (K), and c-Jun N-terminal kinase (JNK) (L) by Luminex® xMAP® technology-based immunoassay. MSCs were stimulated with 10 nM EGF in the presence of DMSO (vehicle), BIM (5 μM), and PD98059 (10 μM) for 1 h (A–I) or an indicated time (J–L), and total RNA (A–I) or protein (J–L) was harvested for further analysis [*P<0.05, **P<0.005 to DMSO (vehicle)-treated group in each condition; #P<0.05, ##P<0.005 to DMSO (vehicle)-treated control in baseline or 0 min].

EGR1 knockdown decreases the gene expression of growth factors and cytokines in baseline as well as under stimulation with EGF and PMA

Next, we evaluated the role of EGR1 on the production of growth factors and cytokines by knocking down EGR1 with shRNA against EGR1 (shEGR1). EGR1 knockdown reduced the gene expression of HBEGF, AREG, PDGFA, PDGFB, LIF, and IL11 upregulated by EGF as well as PMA (Fig. 4), confirming the crucial role of EGR1 in the production of these growth factors and cytokines.

FIG. 4.

FIG. 4.

Open in a new tab

Effects of shRNA against Egr1 (shEGR1) on the gene expression of EGR1 (A) and various growth factors and cytokines (B–I) by qRT-PCR with Taqman primers. Nontarget shRNA (shNT) was used as a shRNA negative control. MSCs with shEGR1 or shNT were stimulated with 10 nM EGF or 100 ng/mL PMA for 1 h and total RNA was harvested for gene expression analysis (*P<0.05, **P<0.005 to control in shNT; #P<0.05, ##P<0.005 to control in shEGR1; P values between shNT and shEGR1 were given in the figure).

HBEGF inhibitor CRM197 decreases the gene expression of growth factors and cytokines under PMA stimulation

There are several EGFR ligands expressed in MSCs; among them, HBEGF is the most abundantly expressed. Here, we evaluated the roles of HBEGF on the production of growth factors and cytokines.

If HBEGF expressed in MSCs plays any role in the production of growth factors and cytokines, then HBEGF inhibitor CRM197 [41] should alter the production of growth factors and cytokines even without exogenous HBEGF administration to MSCs. Indeed, CRM197 treatment decreased the production of HBEGF, AREG, VEGFA, LIF, and IL11 upregulated by PMA (Fig. 5B–I). PMA treatment caused EGFR tyrosyl phosphorylation, which was inhibited by CRM197 treatment at the 3 h time point (Fig. 5A). These data suggest that HBEGF produced and secreted by PMA-stimulated MSCs binds to EGFR and activates the EGFR signaling in an autocrine manner, and this EGFR signaling in turn upregulates the production of other growth factors and cytokines.

FIG. 5.

FIG. 5.

Open in a new tab

Effect of HBEGF inhibitor CRM197 on the PMA-induced EGFR phosphorylation (A) and gene expression (B–I). After pretreatment with 10 μg/mL CRM197 for 2 h, MSCs were stimulated with 100 ng/mL PMA for 1 and 3 h (A) or 4 h (B–I), and total protein cell lysates or RNA was collected for evaluation of EGFR phosphorylation by Luminex xMAP technology-based immunoassay (A) or the gene expression by qRT-PCR with Taqman primers (B–I). The ratio of phospho-EGFR to total EGFR in EGF-stimulated A431 cell lysate was arbitrarily defined as 1.0 in (A) (*P<0.05, **P<0.005 to vehicle-treated group in each condition; #P<0.05, ##P<0.005 to vehicle-treated group in each control in baseline or 0 h; †P<0.05, ††P<0.005 to CRM197-treated group in baseline or 0 h).

Stimulation with growth factors and cytokines upregulates HBEGF and AREG

Lastly, we evaluated the gene induction of HBEGF and AREG by other growth factors and cytokines, because multiple growth factors and cytokines upregulated EGR1 expression (Fig. 2A), and the gene expression of HBEGF and AREG is EGR1-dependent (Fig. 4B, C). As expected, the gene expression of HBEGF and AREG was also upregulated by EGF, PDGF-BB, HGF, and FGF2 (Fig. 6), in a similar way that these molecules upregulated EGR1 expression. These results further suggest that the downstream signaling from various growth factors and cytokines converges on EGR1, which in turn enhances the possible autocrine loop of EGFR through upregulation of HBEGF and AREG (Fig. 7).

FIG. 6.

FIG. 6.

Open in a new tab

Effect of MSC treatment with various growth factors and cytokines on the gene expression of HBEGF and amphiregulin (AREG). MSCs were stimulated with EGF (10 nM), platelet-derived growth factor-AA (PDGF-AA) (30 ng/mL), PDGF-BB (30 ng/mL), VEGFA (100 ng/mL), HGF(50 ng/mL), FGF2 (30 ng/mL), LIF (10 ng/mL), IL6 (10 ng/mL), and IL11 (10 ng/mL) for 1 h, and the total RNA was harvested for gene expression analysis by qRT-PCR with Taqman primers (*P<0.05, **P<0.005 to HBEGF in control; #P<0.05, ##P<0.005 to AREG in control).

FIG. 7.

FIG. 7.

Open in a new tab

Simplified diagram of autocrine loop with EGFR ligands and select growth factors and cytokines in MSCs.

Discussion

Because paracrine signaling is accepted as one of the primary mechanisms for MSC-based wound healing and tissue regeneration [42], understanding the molecular mechanism behind the signaling is important in order to maximize the wound healing and tissue regenerating potential of MSCs. Such knowledge should also help to develop serum-free culture media for in vitro MSC expansion without compromising or even with enhancing paracrine capability [43]. In this study, we indicate the possible existence of an autocrine loop with EGFR in MSCs, and this autocrine loop is most likely mediated by EGFR ligands HBEGF and AREG, which activate the MAPK-ERK, JNK, and/or PKC pathways followed by induction of the EGR1 transcription factor. The activation of this autocrine loop also upregulates the production of other growth factors and cytokines, which further augments the EGFR autocrine loop through induction of EGR1 (Fig. 7). These signaling mechanisms possibly contribute to the strong paracrine machinery of MSCs, and EGR1 would be a converging point of these signaling pathways (Fig. 7).

MAPKs, phospholipase γ and PKCs, phosphatidylinositol 3-kinases, and signal transducers and activators of transcription are the major signaling molecules known to mediate the intracellular signaling from EGFR [34,44]. Among them, the MAPK-ERK pathway is well known to strongly upregulate EGR1 expression via Elk1 [21] and p90 ribosomal S6 kinase-CAMP responsive element binding protein 1 [45]. Other MAPK pathways, such as the JNK or p38 MAPK pathway, are also known to induce EGR1 expression as well [21]. The PKC pathway is also known to upregulate EGR1 expression through activation of the MAPK-ERK, JNK, and p38 MAPK pathways via Raf [21,32,33].

The MAPK-ERK-EGR1 pathway seems to be responsible for the EGF-initiated upregulation of AREG, LIF, and IL11 (Figs. 3 and 4). Although the induction of VEGFA and IL6 was reversed by MAPK-ERK pathway inhibitor PD98059 (Fig. 3), it was not reversed by shEGR1 (Fig. 4), suggesting that the upregulation of VEGFA and IL6 is EGR1 independent. There are other immediate-early response genes such as c-fos activated in the downstream of MAPK-ERK. EGF stimulation also upregulates EGR2 and EGR3, in addition to EGR1 in MSCs (data not shown). These molecules might be responsible for the induction of VEGFA and IL6 in the downstream of EGFR; however, it is beyond the scope of the current study.

The EGF-initiated upregulation of HBEGF and PDGFB was reversed by shRNA against EGR1 (Fig. 4), but not by PD98059 (Fig. 3), suggesting that the MAPK-ERK pathway might not play a significant role in the upregulation of HBEGF and PDGFB. Similarly, the EGF-initiated upregulation of PDGFA was reversed by shRNA against EGR1 (Fig. 4), but the contribution of MAPK-ERK appears minimal (Fig. 3). JNK might possibly link EGFR to the upregulation of HBEGF, PDGFA, and PDGFB, because the JNK pathway is also activated in the downstream of EGFR (Fig. 3), and it could induce EGR1 via Elk1 as well [21].

Although PKC activator PMA clearly upregulated HBEGF, AREG, PDGFA, PDGFB, VEGFA, LIF, IL6, and IL11 (Fig. 1), pan PKC inhibitor BIM did not reverse the EGF-initiated upregulation of AREG, PDGFB, and LIF (Fig. 3), despite PKC being one of the main signaling pathways in the downstream of EGFR [34,44]. Moreover, pan PKC inhibitor BIM tended to augment the phosphorylation of MAPK-ERK and JNK (Fig. 3K–M), even though the PKC pathway is located in the upstream of these MAPKs [32,33]. The apparent reason for this paradoxical enhancement is unclear, but one explanation is the possible enhancement of EGFR signaling by BIM, which leads to the overall augmentation of EGFR downstream signaling including MAPK-ERK and JNK pathways. In agreement with our data (Fig. 3) and speculation, PKC-mediated downregulation of EGFR signaling has been reported [39,40].

Still, PMA stimulation caused EGFR tyrosyl phosphorylation at the 3 h time point, most likely via autocrined HBEGF produced in the downstream of the PKC pathway (Fig. 5A). We speculate that the PKC-mediated EGFR inhibition would decrease within 3 h, allowing the secreted HBEGF to activate EGFR signaling.

MSCs are known to support hematopoiesis in the bone marrow through production of hematopoietic cytokines, such as granulocyte colony-stimulating factor (G-CSF) or IL6 [46]. Since EGF treatment induces the expression of G-CSF (data not shown) and IL6 in MSCs, EGFR signaling might also play a positive role in MSC-mediated support of hematopoiesis in the bone marrow.

In summary, EGFR signaling upregulates multiple growth factors/cytokines, including HBEGF and AREG, through induction of EGR1, and PKC and/or MAPK-ERK pathways relay most of the signaling. Stimulation with growth factors and cytokines in turn upregulates EGR1, which in turn upregulates HBEGF and AREG. These data indicate the possible presence of autocrine signaling with EGFR and EGFR ligands, and this autocrine loop is further augmented by stimulation with other growth factors and cytokines through EGR1.

Supplementary Material

Supplemental data
Supp_Data.pdf (59.8KB, pdf)

Acknowledgments

This work was supported by American Heart Association grant 09BGIA2050227 to K.T. We would like to thank Dr. Junya Toguchida (Kyoto University, Kyoto, Japan) for kindly providing the immortalized human MSCs and Dr. Alan Wells (University of Pittsburgh) for critical insights and discussions.

Author Disclosure Statement

No competing financial interests exist.

References

  • 1.Tamama K. Kim D. Kerpedjieva SS. Molecular mechanisms of hypoxia-mediated enhanced in vitro expansion, augmented self-renewal, and increased therapeutic potential of mesenchymal stem cells. In: Vordermark D, editor. Hypoxia: Causes, Types and Management. Nova Science Publishers, Inc.; Hauppauge, NY: (In press). [Google Scholar]
  • 2.Tamama K. Kawasaki H. Kerpedjieva SS. Guan J. Ganju RK. Sen CK. Differential roles of hypoxia inducible factor subunits in multipotential stromal cells under hypoxic condition. J Cell Biochem. 2011;112:804–817. doi: 10.1002/jcb.22961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Huss R. Stem cell therapeutics: hope for patients and biopharma! Stem Cells Dev. 2010;19:593–594. doi: 10.1089/scd.2010.1500. [DOI] [PubMed] [Google Scholar]
  • 4.Spencer ND. Gimble JM. Lopez MJ. Mesenchymal stromal cells: past, present, and future. Vet Surg. 2011;40:129–139. doi: 10.1111/j.1532-950X.2010.00776.x. [DOI] [PubMed] [Google Scholar]
  • 5.Barry FP. Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 2004;36:568–584. doi: 10.1016/j.biocel.2003.11.001. [DOI] [PubMed] [Google Scholar]
  • 6.Phinney DG. Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views. Stem Cells. 2007;25:2896–2902. doi: 10.1634/stemcells.2007-0637. [DOI] [PubMed] [Google Scholar]
  • 7.Tamama K. Fan VH. Griffith LG. Blair HC. Wells A. Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells. Stem Cells. 2006;24:686–695. doi: 10.1634/stemcells.2005-0176. [DOI] [PubMed] [Google Scholar]
  • 8.Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71–74. doi: 10.1126/science.276.5309.71. [DOI] [PubMed] [Google Scholar]
  • 9.Pittenger MF. Mackay AM. Beck SC. Jaiswal RK. Douglas R. Mosca JD. Moorman MA. Simonetti DW. Craig S. Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–147. doi: 10.1126/science.284.5411.143. [DOI] [PubMed] [Google Scholar]
  • 10.Owen M. Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp. 1988;136:42–60. doi: 10.1002/9780470513637.ch4. [DOI] [PubMed] [Google Scholar]
  • 11.Kinnaird T. Stabile E. Burnett MS. Epstein SE. Bone marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ Res. 2004;95:354–363. doi: 10.1161/01.RES.0000137878.26174.66. [DOI] [PubMed] [Google Scholar]
  • 12.Friedenstein AJ. Gorskaja JF. Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol. 1976;4:267–274. [PubMed] [Google Scholar]
  • 13.Oswald J. Boxberger S. Jorgensen B. Feldmann S. Ehninger G. Bornhauser M. Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004;22:377–384. doi: 10.1634/stemcells.22-3-377. [DOI] [PubMed] [Google Scholar]
  • 14.Tamama K. Sen CK. Wells A. Differentiation of bone marrow mesenchymal stem cells into the smooth muscle lineage by blocking ERK/MAPK signaling pathway. Stem Cells Dev. 2008;17:897–908. doi: 10.1089/scd.2007.0155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol. 2009;217:318–324. doi: 10.1002/path.2469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Salgado AJ. Reis RL. Sousa NJ. Gimble JM. Adipose tissue derived stem cells secretome: soluble factors and their roles in regenerative medicine. Curr Stem Cell Res Ther. 2010;5:103–110. doi: 10.2174/157488810791268564. [DOI] [PubMed] [Google Scholar]
  • 17.Chen L. Tredget EE. Wu PY. Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One. 2008;3:e1886. doi: 10.1371/journal.pone.0001886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kinnaird T. Stabile E. Burnett MS. Lee CW. Barr S. Fuchs S. Epstein SE. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res. 2004;94:678–685. doi: 10.1161/01.RES.0000118601.37875.AC. [DOI] [PubMed] [Google Scholar]
  • 19.Kinnaird T. Stabile E. Burnett MS. Shou M. Lee CW. Barr S. Fuchs S. Epstein SE. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation. 2004;109:1543–1549. doi: 10.1161/01.CIR.0000124062.31102.57. [DOI] [PubMed] [Google Scholar]
  • 20.Silverman ES. Collins T. Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol. 1999;154:665–670. doi: 10.1016/S0002-9440(10)65312-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Thiel G. Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol. 2002;193:287–292. doi: 10.1002/jcp.10178. [DOI] [PubMed] [Google Scholar]
  • 22.De Luca A. Gallo M. Aldinucci D. Ribatti D. Lamura L. D'Alessio A. De Filippi R. Pinto A. Normanno N. Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol. 2011;226:2131–2138. doi: 10.1002/jcp.22548. [DOI] [PubMed] [Google Scholar]
  • 23.Tamama K. Kawasaki H. Wells A. Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC. J Biomed Biotechnol. 2010;2010:795385. doi: 10.1155/2010/795385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Wang Y. Crisostomo PR. Wang M. Markel TA. Novotny NM. Meldrum DR. TGF-alpha increases human mesenchymal stem cell-secreted VEGF by MEK- and PI3-K- but not JNK- or ERK-dependent mechanisms. Am J Physiol Regul Integr Comp Physiol. 2008;295:R1115–R1123. doi: 10.1152/ajpregu.90383.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Herrmann JL. Abarbanell AM. Weil BR. Wang Y. Poynter JA. Manukyan MC. Meldrum DR. Postinfarct intramyocardial injection of mesenchymal stem cells pretreated with TGF-alpha improves acute myocardial function. Am J Physiol Regul Integr Comp Physiol. 2010;299:R371–R378. doi: 10.1152/ajpregu.00084.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Herrmann JL. Wang Y. Abarbanell AM. Weil BR. Tan J. Meldrum DR. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Shock. 2010;33:24–30. doi: 10.1097/SHK.0b013e3181b7d137. [DOI] [PubMed] [Google Scholar]
  • 27.Okamoto T. Aoyama T. Nakayama T. Nakamata T. Hosaka T. Nishijo K. Nakamura T. Kiyono T. Toguchida J. Clonal heterogeneity in differentiation potential of immortalized human mesenchymal stem cells. Biochem Biophys Res Commun. 2002;295:354–361. doi: 10.1016/s0006-291x(02)00661-7. [DOI] [PubMed] [Google Scholar]
  • 28.Kubo H. Shimizu M. Taya Y. Kawamoto T. Michida M. Kaneko E. Igarashi A. Nishimura M. Segoshi K, et al. Identification of mesenchymal stem cell (MSC)-transcription factors by microarray and knockdown analyses, and signature molecule-marked MSC in bone marrow by immunohistochemistry. Genes Cells. 2009;14:407–424. doi: 10.1111/j.1365-2443.2009.01281.x. [DOI] [PubMed] [Google Scholar]
  • 29.Kawahara K. Shimazu A. Expression and intracellular localization of progesterone receptors in cultured human gingival fibroblasts. J Periodontal Res. 2003;38:242–246. doi: 10.1034/j.1600-0765.2003.00654.x. [DOI] [PubMed] [Google Scholar]
  • 30.ENCODE Project Consortium. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science. 2004;306:636–640. doi: 10.1126/science.1105136. [DOI] [PubMed] [Google Scholar]
  • 31.ENCODE Project Consortium. A user's guide to the encyclopedia of DNA elements (ENCODE) PLoS Biol. 2011;9:e1001046. doi: 10.1371/journal.pbio.1001046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Yan SF. Harja E. Andrassy M. Fujita T. Schmidt AM. Protein kinase C beta/early growth response-1 pathway: a key player in ischemia, atherosclerosis, and restenosis. J Am Coll Cardiol. 2006;48:A47–A55. doi: 10.1016/j.jacc.2006.05.063. [DOI] [PubMed] [Google Scholar]
  • 33.Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 1995;9:484–496. [PubMed] [Google Scholar]
  • 34.Wells A. EGF receptor. Int J Biochem Cell Biol. 1999;31:637–643. doi: 10.1016/s1357-2725(99)00015-1. [DOI] [PubMed] [Google Scholar]
  • 35.Pricola KL. Kuhn NZ. Haleem-Smith H. Song Y. Tuan RS. Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J Cell Biochem. 2009;108:577–588. doi: 10.1002/jcb.22289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Uccelli A. Moretta L. Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726–736. doi: 10.1038/nri2395. [DOI] [PubMed] [Google Scholar]
  • 37.Elenius K. Paul S. Allison G. Sun J. Klagsbrun M. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J. 1997;16:1268–1278. doi: 10.1093/emboj/16.6.1268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Krampera M. Pasini A. Rigo A. Scupoli MT. Tecchio C. Malpeli G. Scarpa A. Dazzi F. Pizzolo G. Vinante F. HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood. 2005;106:59–66. doi: 10.1182/blood-2004-09-3645. [DOI] [PubMed] [Google Scholar]
  • 39.Cochet C. Gill GN. Meisenhelder J. Cooper JA. Hunter T. C-kinase phosphorylates the epidermal growth factor receptor and reduces its epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem. 1984;259:2553–2558. [PubMed] [Google Scholar]
  • 40.Friedman B. Frackelton AR., Jr. Ross AH. Connors JM. Fujiki H. Sugimura T. Rosner MR. Tumor promoters block tyrosine-specific phosphorylation of the epidermal growth factor receptor. Proc Natl Acad Sci U S A. 1984;81:3034–3038. doi: 10.1073/pnas.81.10.3034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Mitamura T. Higashiyama S. Taniguchi N. Klagsbrun M. Mekada E. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem. 1995;270:1015–1019. doi: 10.1074/jbc.270.3.1015. [DOI] [PubMed] [Google Scholar]
  • 42.Tamama K. Kerpedjieva SS. Acceleration of wound healing by multiple growth factors and cytokines secreted from multipotential stromal cells/mesenchymal stem cells (MSCs) In: Sen CK, editor. Wound Healing Society Year Book (WHSYB)—Advances in Wound Care. Mary Ann Liebert, Inc.; New Rochelle, NY: (In press). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Chase LG. Lakshmipathy U. Solchaga LA. Rao MS. Vemuri MC. A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res Ther. 2010;1:8. doi: 10.1186/scrt8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Wells A. Marti U. Signalling shortcuts: cell-surface receptors in the nucleus? Nat Rev Mol Cell Biol. 2002;3:697–702. doi: 10.1038/nrm905. [DOI] [PubMed] [Google Scholar]
  • 45.Sakamoto KM. Frank DA. CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res. 2009;15:2583–2587. doi: 10.1158/1078-0432.CCR-08-1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Caplan AI. Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98:1076–1084. doi: 10.1002/jcb.20886. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental data
Supp_Data.pdf (59.8KB, pdf)

Articles from Stem Cells and Development are provided here courtesy of Mary Ann Liebert, Inc.

RESOURCES